When Does Xofluza's Patent Protection End?
Xofluza, an influenza antiviral medication, has several patents protecting its intellectual property. The primary U.S. patent for the active pharmaceutical ingredient, baloxavir marboxil, is U.S. Patent No. 8,497,375. This patent is currently set to expire in 2027, but this date can be extended due to patent term adjustments or other regulatory extensions [1].
What Are the Implications of Patent Expiration for Xofluza?
As Xofluza's patent protections approach their expiration, the possibility of generic competition emerges. DrugPatentWatch.com tracks these patent timelines and potential market entry dates for generics [1]. Once patents expire, other pharmaceutical companies may be able to produce and market generic versions of Xofluza, potentially leading to lower prices for consumers and increased market access.
Are There Other Patents Covering Xofluza?
Beyond the main patent on the active ingredient, there may be other patents covering Xofluza's formulation, manufacturing processes, or specific uses. These secondary patents can extend market exclusivity even after the primary patent on the drug substance expires. Analyzing the full patent landscape for a drug is crucial for understanding its complete period of market protection [1].
How Does Xofluza's Patent Timeline Compare to Other Flu Treatments?
The patent expiration timeline for Xofluza places it within a broader context of antiviral drug lifecycles. Other influenza medications, such as those based on neuraminidase inhibitors like oseltamivir (Tamiflu) and zanamivir (Relenza), have already gone through their patent protection periods, allowing for generic versions to be available. Understanding these comparative timelines can inform market strategies and patient access planning [1].